In the fall of 2025, Chinese researchers put chronic‑myeloid‑leukemia (CML) on the world stage. At the 27th John Goldman Conference of the European School of Hematology in Lisbon, Professor Li Weiming unveiled olverembatinib as a second‑line oral therapy for chronic‑phase CML—marking the drug’s debut at an international forum and showcasing China’s home‑grown medicines to a global audience. Later that year, at the 67th ASH Annual Meeting in Orlando, a team of five Chinese CML specialists presented a cutting‑edge AI model that predicts a patient’s chance of achieving treatment‑free remission (TFR). Their data highlighted that, when the length of deep molecular response is accounted for, the classic drugs imatinib and nilotinib perform on par with newer agents such as flumatinib and olverembatinib. The AI tool offers clinicians a practical way to identify patients who could safely stop therapy, turning a hopeful concept into a realistic goal. Back in April, Professors Hu Yu and Li Weiming led 24 experts from 15 hospitals in translating the second edition of the international monograph “Chronic Myeloid Leukemia.” This landmark Chinese‑language handbook fills a long‑standing gap, standardising diagnosis and treatment across the country and cementing China’s role as a leader in CML research and care.
Read more